Summary | Patience is the name of the game for Gilead Sciences
Inc. There's a growing clamor for the Forest City, Calif.
biotech to do something with its $14.7 billion stockpile of
cash and equivalents amidst a frenzy of big pharmaceutical
deals. But finance chief Robin Washington isn't easily swayed.
Inc. There's a growing clamor for the Forest City, Calif.
biotech to do something with its $14.7 billion stockpile of
cash and equivalents amidst a frenzy of big pharmaceutical
deals. But finance chief Robin Washington isn't easily swayed.
blogs.wsj.com | 30 July 2015